Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
systemic antifungal agents, miconazole derivatives	4874	164650-44-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: efinaconazole jublia KP-103	Efinaconazole is an azole antifungal. Efinaconazole inhibits fungal lanosterol 14α-demethylase involved in the biosynthesis of ergosterol, a constituent of fungal cell membranes. Molecular weight: 348.40 Formula: C18H22F2N4O CLOGP: 2.42 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 54.18 ALOGS: -2.76 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

efinaconazole
jublia
KP-103

Efinaconazole is an azole antifungal. Efinaconazole inhibits fungal lanosterol 14α-demethylase involved in the biosynthesis of ergosterol, a constituent of fungal cell membranes.

Molecular weight: 348.40
Formula: C18H22F2N4O
CLOGP: 2.42
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 54.18
ALOGS: -2.76
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
kinase-safety-class	ACVR2B,BRAF,CDK5,EIF2AK3,GRK2,NTRK2,PDK1,PDK2,PDK4,TGFBR1	10
pfas-class	PFAS structural alert (1 = True, 0 = False)	0

Approvals:

Date	Agency	Company	Orphan
July 4, 2014	PMDA
June 6, 2014	FDA	DOW PHARM

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bronchopulmonary aspergillosis allergic	317.30	37.96	66	4754	3700	90619927
Lung opacity	285.57	37.96	66	4754	6036	90617591
Total lung capacity decreased	265.21	37.96	57	4763	3738	90619889
Blood calcium increased	240.93	37.96	66	4754	11992	90611635
Aspiration	228.12	37.96	67	4753	15626	90608001
Rales	223.17	37.96	66	4754	15761	90607866
Sputum discoloured	206.69	37.96	66	4754	20325	90603302
Blood test abnormal	204.93	37.96	66	4754	20886	90602741
Bronchiectasis	200.80	37.96	66	4754	22264	90601363
Obstructive airways disorder	191.27	37.96	66	4754	25803	90597824
Haemoptysis	174.96	37.96	66	4754	33254	90590373
Transaminases increased	167.90	37.96	66	4754	37126	90586501
Pleuritic pain	136.02	37.96	41	4779	10420	90613207
Hypoxia	125.79	37.96	66	4754	72333	90551294
Pulmonary mass	119.15	37.96	48	4772	28724	90594903
Liver function test increased	118.67	37.96	67	4753	84788	90538839
Blood creatinine increased	107.61	37.96	67	4753	101319	90522308
Pulmonary fibrosis	101.54	37.96	66	4754	107437	90516190
Upper respiratory tract infection	93.24	37.96	67	4753	128251	90495376
Pleural effusion	87.19	37.96	61	4759	111930	90511697
Gastrooesophageal reflux disease	86.12	37.96	71	4749	166266	90457361
Tremor	84.81	37.96	68	4752	153105	90470522
Oedema peripheral	77.03	37.96	81	4739	257834	90365793
Obstructive defaecation	68.77	37.96	12	4808	258	90623369
Stoma site dermatitis	68.08	37.96	12	4808	274	90623353
Pneumococcal infection	66.43	37.96	15	4805	1230	90622397
Gastrointestinal stoma output abnormal	63.47	37.96	12	4808	408	90623219
Cough	58.20	37.96	84	4736	368878	90254749
Asthma	56.67	37.96	67	4753	242093	90381534
Stoma site inflammation	56.16	37.96	12	4808	762	90622865
Lower respiratory tract infection	53.19	37.96	66	4754	250593	90373034
Constipation	51.92	37.96	69	4751	280326	90343301
Asthenia	51.07	37.96	97	4723	533654	90089973
Underweight	49.16	37.96	12	4808	1378	90622249
Stoma site pain	48.93	37.96	12	4808	1405	90622222
Product dose omission issue	45.35	37.96	66	4754	291621	90332006
Musculoskeletal stiffness	44.51	37.96	66	4754	296466	90327161
Gastrointestinal stoma complication	42.57	37.96	12	4808	2407	90621220
Wheezing	41.62	37.96	57	4763	238023	90385604
Abdominal pain upper	41.51	37.96	68	4752	332606	90291021
Hiccups	39.92	37.96	12	4808	3014	90620613
Faeces hard	39.10	37.96	12	4808	3230	90620397
Anaemia	38.57	37.96	68	4752	352734	90270893
Metabolic alkalosis	38.03	37.96	12	4808	3537	90620090
Osteogenesis imperfecta	37.99	37.96	9	4811	911	90622716

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bronchopulmonary aspergillosis allergic	132.90	63.71	37	3493	4561	42613244
Congenital hiatus hernia	126.43	63.71	38	3492	6136	42611669
Anticoagulant therapy	115.23	63.71	33	3497	4502	42613303
Antacid therapy	113.94	63.71	33	3497	4684	42613121
Sleep disorder therapy	113.93	63.71	36	3494	6858	42610947
Analgesic therapy	111.69	63.71	35	3495	6489	42611316
Blood calcium increased	106.72	63.71	36	3494	8418	42609387
Hyperphosphataemia	102.27	63.71	39	3491	12965	42604840
Drug therapy	99.99	63.71	32	3498	6348	42611457
Activated partial thromboplastin time prolonged	98.07	63.71	40	3490	15863	42601942
Pleuritic pain	92.73	63.71	31	3499	7046	42610759
Myasthenia gravis	90.73	63.71	38	3492	16099	42601706
Blood test abnormal	88.34	63.71	35	3495	12871	42604934
Hypophosphataemia	84.33	63.71	39	3491	20906	42596899
Aspiration	83.73	63.71	37	3493	17849	42599956
Breath sounds abnormal	79.99	63.71	32	3498	12061	42605744
Bacterial infection	79.47	63.71	41	3489	27838	42589967
Micturition urgency	77.02	63.71	31	3499	11867	42605938
End stage renal disease	76.68	63.71	34	3496	16524	42601281
Incorrect route of product administration	75.84	63.71	38	3492	24267	42593538
Neuralgia	73.91	63.71	38	3492	25609	42592196
Joint injury	70.75	63.71	31	3499	14645	42603160
Ulcer	70.52	63.71	32	3498	16409	42601396
Hyperlipidaemia	68.18	63.71	34	3496	21482	42596323
Hypercholesterolaemia	64.73	63.71	28	3502	12821	42604984

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bronchopulmonary aspergillosis allergic	441.60	43.09	107	8329	8319	110572544
Blood calcium increased	356.51	43.09	106	8330	17934	110562929
Aspiration	309.35	43.09	108	8328	30425	110550438
Total lung capacity decreased	305.43	43.09	77	8359	7037	110573826
Blood test abnormal	304.73	43.09	105	8331	28449	110552414
Lung opacity	290.29	43.09	82	8354	11570	110569293
Pleuritic pain	234.77	43.09	75	8361	16065	110564798
Rales	233.33	43.09	83	8353	24656	110556207
Sputum discoloured	223.46	43.09	83	8353	27862	110553001
Transaminases increased	214.39	43.09	102	8334	63288	110517575
Bronchiectasis	201.95	43.09	83	8353	36410	110544453
Obstructive airways disorder	183.20	43.09	83	8353	46066	110534797
Upper respiratory tract infection	161.78	43.09	109	8327	131219	110449644
Haemoptysis	148.94	43.09	83	8353	71271	110509592
Pulmonary mass	141.44	43.09	65	8371	37236	110543627
Blood creatinine increased	135.81	43.09	112	8324	182777	110398086
Liver function test increased	134.84	43.09	84	8352	88464	110492399
Congenital hiatus hernia	133.28	43.09	39	8397	6220	110574643
Pulmonary fibrosis	123.94	43.09	84	8352	101958	110478905
Sleep disorder therapy	122.25	43.09	38	8398	7433	110573430
Anticoagulant therapy	121.21	43.09	35	8401	5326	110575537
Antacid therapy	120.43	43.09	35	8401	5449	110575414
Tremor	120.07	43.09	109	8327	202123	110378740
Analgesic therapy	118.98	43.09	37	8399	7247	110573616
Drug therapy	106.47	43.09	34	8402	7257	110573606
Lower respiratory tract infection	104.88	43.09	110	8326	242996	110337867
Hypoxia	103.85	43.09	83	8353	129432	110451431
Hyperphosphataemia	103.47	43.09	41	8395	16340	110564523
Asthma	98.71	43.09	108	8328	250183	110330680
Oedema peripheral	96.67	43.09	122	8314	328538	110252325
Activated partial thromboplastin time prolonged	94.34	43.09	42	8394	22326	110558537
Gastrooesophageal reflux disease	89.55	43.09	88	8348	179888	110400975
Myasthenia gravis	89.47	43.09	40	8396	21471	110559392
Musculoskeletal stiffness	88.89	43.09	108	8328	279714	110301149
Pleural effusion	81.24	43.09	83	8353	177626	110403237
Product dose omission issue	76.97	43.09	108	8328	321674	110259189
End stage renal disease	76.95	43.09	36	8400	21437	110559426
Hypophosphataemia	73.02	43.09	40	8396	33142	110547721
Benign prostatic hyperplasia	72.95	43.09	33	8403	18201	110562662
Neuralgia	68.76	43.09	44	8392	48434	110532429
Bacterial infection	68.32	43.09	43	8393	45993	110534870
Micturition urgency	68.02	43.09	32	8404	19288	110561575
Breath sounds abnormal	65.40	43.09	34	8402	25370	110555493
Obstructive defaecation	64.80	43.09	12	8424	250	110580613
Stoma site dermatitis	63.22	43.09	12	8424	287	110580576
Hyperlipidaemia	62.19	43.09	37	8399	35811	110545052
Drug hypersensitivity	61.69	43.09	118	8318	453972	110126891
Gout	58.93	43.09	36	8400	36530	110544333
Gastrointestinal stoma output abnormal	58.81	43.09	12	8424	420	110580443
Troponin increased	57.65	43.09	33	8403	29733	110551130
Respiratory symptom	56.48	43.09	26	8410	14919	110565944
Asthenia	56.25	43.09	146	8290	688853	109892010
Pneumococcal infection	55.40	43.09	15	8421	1804	110579059
Ulcer	51.12	43.09	35	8401	43081	110537782
Stress	49.54	43.09	50	8386	105298	110475565
Incorrect route of product administration	49.05	43.09	40	8396	64021	110516842
Cardiovascular disorder	48.87	43.09	27	8409	22733	110558130
Stoma site inflammation	48.37	43.09	12	8424	1023	110579840
Cough	47.44	43.09	107	8329	461534	110119329
Constipation	47.34	43.09	92	8344	357694	110223169
Wheezing	47.16	43.09	76	8360	255154	110325709
Joint injury	46.31	43.09	32	8404	39962	110540901
Underweight	43.72	43.09	12	8424	1518	110579345

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	D01AC19	DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Imidazole and triazole derivatives
FDA CS	M0002083	Azoles
FDA EPC	N0000175487	Azole Antifungal
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000935	Antifungal Agents
CHEBI has role	CHEBI:77884	EC 1.14.13.70 (sterol 14α-demethylase) inhibitor

Related Drugs by ATC class:

D01AC Imidazole and triazole derivatives 20 drugs

bifonazole chlormidazole clotrimazole eberconazole econazole fenticonazole fluconazole flutrimazole isoconazole ketoconazole lanoconazole luliconazole show all 20 →

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID
Onychomycosis due to Trichophyton mentagrophytes	indication	23549005
Onychomycosis due to dermatophyte	indication	402134005
Onychomycosis of toenails	indication	403059006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.3	acidic
pKa2	7.37	Basic
pKa3	1.38	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
10%	JUBLIA	BAUSCH	N203567	June 6, 2014	RX	SOLUTION	TOPICAL	7214506	Feb. 22, 2026	ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS
10%	JUBLIA	BAUSCH	N203567	June 6, 2014	RX	SOLUTION	TOPICAL	10512640	Jan. 3, 2028	TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
10%	JUBLIA	BAUSCH	N203567	June 6, 2014	RX	SOLUTION	TOPICAL	11213519	Jan. 3, 2028	ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS; TOPICAL TREATMENT OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
10%	JUBLIA	BAUSCH	N203567	June 6, 2014	RX	SOLUTION	TOPICAL	11872218	Jan. 3, 2028	TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
10%	JUBLIA	BAUSCH	N203567	June 6, 2014	RX	SOLUTION	TOPICAL	9566272	Jan. 3, 2028	TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
10%	JUBLIA	BAUSCH	N203567	June 6, 2014	RX	SOLUTION	TOPICAL	9877955	Jan. 3, 2028	TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
10%	JUBLIA	BAUSCH	N203567	June 6, 2014	RX	SOLUTION	TOPICAL	8039494	July 8, 2030	ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS
10%	JUBLIA	BAUSCH	N203567	June 6, 2014	RX	SOLUTION	TOPICAL	10342875	Oct. 2, 2034	ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS; TOPICAL TREATMENT OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
10%	JUBLIA	BAUSCH	N203567	June 6, 2014	RX	SOLUTION	TOPICAL	10828293	Oct. 2, 2034	ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS; TOPICAL TREATMENT OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
10%	JUBLIA	BAUSCH	N203567	June 6, 2014	RX	SOLUTION	TOPICAL	10864274	Oct. 2, 2034	ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS; TOPICAL TREATMENT OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
10%	JUBLIA	BAUSCH	N203567	June 6, 2014	RX	SOLUTION	TOPICAL	11654139	Oct. 2, 2034	TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES
10%	JUBLIA	BAUSCH	N203567	June 6, 2014	RX	SOLUTION	TOPICAL	10478601	April 25, 2035	TOPICAL TREATMENT OF TINEA UNGUIUM BY USING AN APPLICATOR FOR APPLYING A SOLUTION FOR TREATING TINEA UNGUIUM TO AN AFFECTED PART OF A PATIENT

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Lanosterol 14-alpha demethylase	Enzyme		F2SHH3_TRIRC	INHIBITOR				CHEMBL	CHEMBL

External reference:

ID	Source
D10021	KEGG_DRUG
4033415	VUID
N0000190763	NUI
4033415	VANDF
CHEBI:82718	CHEBI
CHEMBL2103877	ChEMBL_ID
C431707	MESH_SUPPLEMENTAL_RECORD_UI
DB09040	DRUGBANK_ID
1539753	RXNORM
221737	MMSL
30345	MMSL
015550	NDDF
703880007	SNOMEDCT_US
703881006	SNOMEDCT_US
C3273754	UMLSCUI
9349	INN_ID
489181	PUBCHEM_CID
J82SB7FXWB	UNII

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
JUBLIA	HUMAN PRESCRIPTION DRUG LABEL	1	0187-5400	SOLUTION	100 mg	TOPICAL	NDA	27 sections

Ask DrugCentral

efinaconazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: